https://www.selleckchem.com/pr....oducts/fluzoparib.ht
Atrial-ventricular differences in voltage-gated Na currents might be exploited for atrial-selective antiarrhythmic drug action for the suppression of atrial fibrillation without risk of ventricular tachyarrhythmia. Eleclazine (GS-6615) is a putative antiarrhythmic drug with properties similar to the prototypical atrial-selective Na channel blocker ranolazine that has been shown to be safe and well tolerated in patients. The present study investigated atrial-ventricular differences in the biophysical properties and inhibition by elecl